Search

everythinglearnresearchcommunity

for

Search:↓

A 43-year-old male has been using oral minoxidil, finasteride, and dutasteride for hair loss, with some stabilization and thin hair growth but no significant cosmetic improvement. He is considering increasing microneedling frequency and exploring other options, as he is concerned about the lack of terminal hair growth.

The user experienced persistent acne and skin issues with dutasteride, leading them to stop its use. They switched to finasteride, which caused mild acne and potential liver concerns, prompting consideration of alternative treatments like topical finasteride and GHK-Cu.

The relative strength of Pyrilutamide compared to RU58841 in terms of androgen receptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

The conversation discusses a last-resort hair loss treatment combining topical finasteride, minoxidil, melatonin, and progesterone, with claims that topical finasteride can inhibit up to 52% of scalp DHT. One reply clarifies that progesterone is not an anti-androgen but has anti-androgenic properties because it competes with androgens for receptors.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

A user shared their positive experience with a 2200 graft FUE hair transplant at DiStefano Hair Restoration in Worcester, MA, praising Dr. Heinis and his staff for their care. The user is also using oral Dutasteride, topical Minoxidil, and vitamins D and B.

The user is experiencing asymmetrical hair loss at the frontal hairline and is concerned about potential conditions like frontal fibrosing alopecia. They have started using finasteride and pumpkin seed oil to address the issue.

GHK-CU is not considered as effective for hair loss as finasteride, minoxidil, or RU58841, with many users reporting minimal benefits. Some users experienced skin improvements, but its impact on hair is debated and often attributed to concurrent use of other treatments.

The user experienced positive hair regrowth using finasteride for two years, with no side effects, and recently added minoxidil foam to address temple volume. Other users shared similar experiences with finasteride, noting varying results and some concerns about side effects, but overall satisfaction with hair maintenance.

The user reported positive hair regrowth results after six months of using 0.5 mg finasteride and nanoxidil, despite experiencing initial side effects like testicular pain and changes in libido. They noted that nanoxidil was chosen over minoxidil due to less scalp irritation.

User asks if stacking Alfatradiol and Fluridil is effective for hair loss. Alfatradiol is a weaker, topical 5ar inhibitor, while Fluridil is an anti-androgen preventing DHT binding to hair follicles.

A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

A user has been treating hair loss with finasteride for two years without success and is experiencing an itchy scalp with seborrhea. Despite low DHT levels, they are still losing hair, suggesting that DHT might not be the main cause of their hair loss, and they are considering other treatments or causes.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.

The user experienced significant hair regrowth using 1mg finasteride daily and Rogaine minoxidil 5% foam twice a day, along with vitamin D supplementation. They also managed stress through lifestyle changes like exercise, quitting nicotine, and improving sleep.

The conversation discusses the potential role of prolactin in hair loss and mentions treatments like HMI115, mucuna pruriens, Zinc, and B6 P5P for lowering prolactin levels. It also touches on the use of natural compounds and the lack of studies due to funding issues.

After a second session of Platelet-Rich Plasma (PRP) treatment for hair regrowth, the user is experiencing increased shedding of thick and dark hairs and is concerned about whether this is temporary. They are seeking others' experiences with PRP, specifically regarding the duration of shedding and eventual positive outcomes.

User seeks Procyanidin B2 supplement source and asks for dosage comparison. Another user requests study details and apple type importance.

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

Androgenetic alopecia is affected by scalp DHT levels, not sensitivity, with treatments like finasteride and dutasteride aiming to optimize these levels. Personalized DHT management is crucial for effective hair growth.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

Hair loss discussion includes finasteride intolerance and questioning if Pyrilutamide is an alternative. Pyrilutamide not commercially available, but may be tolerable if approved since it's not a 5aR inhibitor.

Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

The user reported early stage diffuse hair thinning and increased DHT levels after 4 weeks on Finasteride and 8 weeks on Finasteride plus 4 weeks on Dutasteride, despite the medications being authentic and stored properly. They are considering increasing their Dutasteride dosage due to the lack of side effects and are unsure if the treatment is helping their hair.